DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0256473 A1 Merkus (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0256473 A1 Merkus (43) Pub US 2016O256473A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0256473 A1 Merkus (43) Pub. Date: Sep. 8, 2016 (54) OROMUCOSAL LIQUIDESTRADIOL Publication Classification COMPOSITIONS (51) Int. Cl. (71) Applicant: INNOTESTO BVBA, Kasterlee (BE) A613 L/565 (2006.01) A647/4 (2006.01) (72) Inventor: Franciscus Wilhelmus Henricus Maria A647/10 (2006.01) Merkus, Kasterlee (BE) A619/00 (2006.01) A619/08 (2006.01) (21) Appl. No.: 15/155,410 (52) U.S. C. 1-1. CPC ............... A61 K3I/565 (2013.01); A61 K9/006 (22) Filed: May 16, 2016 (2013.01); A61 K9/08 (2013.01); A61K 47/10 Related U.S. Application Data (2013.01); A61 K47/14 (2013.01) (63) Continuation of application No. 14/370,435, filed on (57) ABSTRACT Jul. 2, 2014, filed as application No. PCT/EP2013/ 050110 on Jan. 4, 2013. The present invention relates to low dose estradiol solutions for oromucosal administration Suitable in replacement (30) Foreign Application Priority Data therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with Jan. 4, 2012 (GB) ................................... 12OOO62.6 low endogenous levels of estradiol in female Subjects. US 2016/0256473 A1 Sep. 8, 2016 OROMUCOSAL LIQUIDESTRADIOL 0007 Formulations of dimethyl-3-cyclodextrin com COMPOSITIONS plexes of 17 B-estradiol and/or progesterone in an aqueous solution for nasal application have been described in EP 0001. The present invention relates to low dose estradiol 0349091. One such formulation containing 17 B-estradiol Solutions for oromucosal administration Suitable in replace complexed in methylated-p-cyclodextrin has been authorized ment therapy or suppletion of low estradiol levels and also for for medical use under the trade name AerodiolTM. This nasal preventing, alleviating or treating symptoms associated with spray product, administered in a low dose of 300 ug/day, was low endogenous levels of estradiol in female Subjects. as effective as a 2 mg oral tablet/day in treating menopausal symptoms. It showed reduced adverse effects, i.e. fewer inci BACKGROUND OF THE INVENTION dences of mastalgia and withdrawal bleedings. Furthermore, beneficial effects on Some lipid parameters, on markers of 0002 Current estradiol therapy includes oral, transder bone resorption, bone formation and bone mineral density mal, injectable and vaginal formulations. Transdermal deliv were reported. Finally, less breast tenderness was found with ery comprises patches, gels, lotions and sprays, while Vaginal intranasal administration of estradiol as compared to oral products include Suppositories, creams, and rings. treatment. 0003) Estradiol, when taken orally as tablets, pills or cap 0008 Because of the side effects of frequent nasal admin Sules, is converted for a large part to estrone after absorption istration, AerodiolTM is recommended for once daily admin in the gastrointestinal tract and metabolism in the liver (first istration in a high dose resulting in high peak estradiol levels. pass metabolism). This causes an imbalance in the estradiol/ These are reached within 10-30 min. and the levels return to estrone ratio, which is normally 1:1 in premenstrual women. 10% of the peak value in about two hours after administration This imbalance is mainly responsible for a change in lipids (Devissaguet et al., Eur. J. Drug Metabol. Pharmacokinetics and clotting factors. Non-oral products (transdermal, vaginal) 1999; 24; 265-271). This means that once daily intranasal avoid this hepatic first-pass metabolism and therefore are administration of AerodiolTM results in a “pulsatile' profile, considered first choice in estradiol Suppletion. comprising one large peak per day, followed by a period 0004. In general, it is advisable to use the lowest dose of during which estradiol levels remain at a low level. Peak the hormone estradiol possible, because overdosing may lead levels after administration of 300 g estradiol by the required to side effects related to unphysiological hormone levels. quantity of AerodiolTM nasal spray reach values of 1400 Low-dose non-oral products are first choice because of (1) the pg/ml. Normal estradiol levels differ slightly per laboratory, low-dose administered, (2) the physiological ratio between but range from 100-500 pg/ml during a menstrual cycle. This levels of estradiol and its metabolite estrone, and (3) as a means that the peak level of 1400 pg/ml, obtained with nasal consequence the decreased risk of adverse effects. The use of AerodiolTM, is about 3 times higher than the highest normal very low doses may also be beneficial as opposed treatment levels in premenopausal women. (continuous or cyclic co-administration of a progestogen) is 0009. A further disadvantage related to nasal administra not an absolute requirement because the endometrium does tion is that the access to the nasal mucosa can be compro not proliferate upon administration of very low doses of estra mised in instances such as common cold or allergy resulting diol. in a running or blocked nose. This results in inconsistent or 0005. In the research into new estradiol products, non-oral even no nasal absorption. The product characteristics of administration has been considered, including products for AerodiolTM teach that in that instance the patient, should nasal and oromucosal administration. U.S. Pat. No. 5,955, administer a double dose of AerodiolTM via the oromucosal 098 discloses a buccal aerosol spray, comprising a propellant route to reach similar estradiol serum levels. 50-95%, a non-polar solvent 5-50%, the active drug com 0010 Moreover, nasal administration may give rise to pound 0.001-15% (including estradiol), and a flavoring agent local side effects in the nose, such as local irritation, itching, 0.05-5%. U.S. Pat. No. 6,110,486 discloses a buccal spray rhinorrhoea, Sneezing and nosebleeds. Multiple nasal admin containing estradiol, dissolved in a pharmacologically istrations increase these undesired side effects. acceptable polar solvent, comprising in weight '% of total 0011. It is a first object of the invention to avoid nasal composition: polar solvent 75-99.8%, active compound 0.68 administration of estradiol and the side effects associated 40%. As solvents for the sprays there are used low molecular therewith. weight polyethylene glycols (PEG) of 200-1000 MW (pref 0012. It is a second object of the invention to provide an erably 200-600) and also low molecular weight alcohols and estradiol composition for oromucosal administration that polyols, such as glycerin and water. Illustrated is a spray does not require the administration of high doses of estradiol. formulation containing estradiol and 85% polyethylene gly Such as for example the double dose required for oromucosal col. However, this solvent has a bitter, burning taste in the administration of AerodiolTM. mouth, making a spray, based mainly on Such an ingredient, 0013 Further, it is an object of the invention to provide a poorly acceptable for chronic use. new dosage regimen for estradiol administration that pro 0006 US 2011/0097405 discloses an oromucosal estra vides a physiological pharmacokinetic profile approaching diol product, which is absorbed mainly in the oral cavity and normal estradiol plasma levels. A particular object is the not in the gastro-intestinal tract. It is a water-soluble film, provision of a dosage regimen with low estradiol peak levels, called wafer. Such wafers containing estradiol in a low dose in particular a regimen that keeps the highest estradiol levels dissolve quickly in the mouth, thereby releasing estradiol. under 500 pg/ml, and avoids the high peak serum levels seen which then can be absorbed via the oromucosal route. Buccal with the administration of existing nasal formulations. tablets comprisingestradiol are disclosed in EP 0371466 and 0014. It is also an object of the invention to provide a new WO 2010/089078. Medicated papers for oromucosal admin and improved dosage form comprising a low dose estradiol istration containing estradiol and a cyclodextrinare described formulation, for application to the oral mucosa, that (1) deliv in EP 1867 321. ers a similar or better bioavailability than nasal administra US 2016/0256473 A1 Sep. 8, 2016 tion, (2) provides a dosage form whereby the dose can be (0023 The dose may have a volume of 10 ul to 300 ul of individualized, (3) with a flexible dosage frequency and (4) said solution, preferably 25ul to 100 ul—for example 25ul, offers better patient compliance. 50 ul or 100 ul. 0024. The oromucosal administration can be by a spray, a SUMMARY OF THE INVENTION dosage pen or a device delivering drops. Thus in a further aspect, the invention provides a dosage form comprising a 0015. In one aspect, the present invention relates to a non spray, a dosage pen or a device delivering drops containing aqueous (or Substantially non-aqueous) solution containing the solution as specified herein. 0.01-0.9% (w/v) of estradiol, or an equivalent amount of a 0025. The estradiol solutions of the invention can be used pharmaceutically acceptable hydrate or ester thereof, 5-30% in a dosage regimen that can be individually adapted by one or (v/v) of a C-C alcohol and 70-95% (v/v) of an ester of a more of the following: 1. by the dose as such, 2. the volume of C-C alcohol and a C-C fatty acid for use in the treatment the sprays or drops, 3. the number of sprays or drops, 4. by a of a human female with decreased estradiol levels by oromu single or multiple administration, 5. at one or more points in cosal administration of a dose of said solution, said dose time, and 6. by the frequency of the daily administrations. The containing 0.01-0.3 mg of estradiol, or an equivalent amount Solution may be administered according to the regimens of a pharmaceutically acceptable hydrate or an ester thereof.
Load more

Recommended publications
  • The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus Cyanogenys
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 1970 The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys William F. McConnell College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Physiology Commons Recommended Citation McConnell, William F., "The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys" (1970). Dissertations, Theses, and Masters Projects. Paper 1539624685. https://dx.doi.org/doi:10.21220/s2-1smx-cy32 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. THE INFLUENCE OF HYPOTHALAMIC STEROID IMPLANTS ON OVULATION AND OVARIAN GROWTH AND FUNCTION IN THE IGUANID LIZARD, SCELOPORUS CYANOGENYS A Thesis Presented to The Faculty of the Department of Biology The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Arts By William F. McConnell 1970 ProQuest Number: 10625114 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Estradiol Acetate Vaginal Ring) Rx Only
    NDA 21-367/S-002 Page 3 PRESCRIBING INFORMATION Femring® (estradiol acetate vaginal ring) Rx Only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (See WARNINGS, Cardiovascular disorders and Dementia.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms, Breast cancer.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]
  • Hormonal and Non-Hormonal Management of Vasomotor Symptoms: a Narrated Review
    Central Journal of Endocrinology, Diabetes & Obesity Review Article Corresponding authors Orkun Tan, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Hormonal and Non-Hormonal and Infertility, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390 and ReproMed Fertility Center, 3800 San Management of Vasomotor Jacinto Dallas, TX 75204, USA, Tel: 214-648-4747; Fax: 214-648-8066; E-mail: [email protected] Submitted: 07 September 2013 Symptoms: A Narrated Review Accepted: 05 October 2013 Orkun Tan1,2*, Anil Pinto2 and Bruce R. Carr1 Published: 07 October 2013 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Copyright and Infertility, University of Texas Southwestern Medical Center, USA © 2013 Tan et al. 2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, ReproMed Fertility Center, USA OPEN ACCESS Abstract Background: Vasomotor symptoms (VMS; hot flashes, hot flushes) are the most common complaints of peri- and postmenopausal women. Therapies include various estrogens and estrogen-progestogen combinations. However, both physicians and patients became concerned about hormone-related therapies following publication of data by the Women’s Health Initiative (WHI) study and have turned to non-hormonal approaches of varying effectiveness and risks. Objective: Comparison of the efficacy of non-hormonal VMS therapies with estrogen replacement therapy (ERT) or ERT combined with progestogen (Menopausal Hormone Treatment; MHT) and the development of literature-based guidelines for the use of hormonal and non-hormonal VMS therapies. Methods: Pubmed, Cochrane Controlled Clinical Trials Register Database and Scopus were searched for relevant clinical trials that provided data on the treatment of VMS up to June 2013.
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Female Hormone Therapy Options
    WOMEN’S INTERNATIONAL PHARMACY FEMALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women’s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for women in menopause and some alternatives. The Women’s International Pharmacy logo is placed throughout the tables to signify the hormones and dosage forms Women’s International Pharmacy compounds. This material is for informational purposes. It is not intended as a substitute for medical advice. Please consult a qualified health care professional for individual health and medical advice. = Compounded by Women’s International Pharmacy Oral Estrogens ORAL ESTROGENS DOSAGES DOSING BIOIDENTICAL AVAILABLE REGIMEN COMMENTS/REFERENCES Estradiol (E2) capsules Any 0.25mg - 2mg once Hargrove J. Infertility & Reproductive (compounding pharmacies) daily. Some may Med Clinic North America 1995; require twice daily 6(4):653-674. dosing. Estriol (E3) capsules Any 1mg - 8mg Head K. Alt Med Rev; 1998; 3(2):101- (compounding pharmacies) once daily or in 113. Hudson T. Women’s Encyclopedia divided doses. of Natural Medicine (Lincolnwood, IL: Keats) 1999:170. Biestrogen (bi-est) capsules Any 1.25mg - 5mg once The 20:80 ratio may be altered to meet 20% estradiol (E2), to twice daily patient need. 80% estriol (E3) McKenna S. The Phytogenic Hormone (compounding pharmacies) Solution (NYC, NY: Villard Books) 2002:189-190. Triestrogen (tri-est, triple 1.25mg - 2.5mg once Although these ratios are commonly Any estrogen) capsules to twice daily used and are based on the research 10% estrone (E1), done by Dr. Jonathan Wright, other formulas are available to accommodate 10% estradiol (E2), individual needs.
    [Show full text]
  • Use of Estrogen-Dihydropyridine Compounds For
    Europaisches Patentamt J European Patent Office © Publication number: 0 220 844 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 86307536.2 © int. ci.<: A61K 31/57 A61 K , 31/565 , A61K 31/44 © Date of filing: 01.10.86 The title of the invention has been amended © Applicant: UNIVERSITY OF FLORIDA (Guidelines for Examination in the EPO, A-lll, 207 Tigert Hall 7.3). Gainesville Florida 32611 (US) @ Inventor: Bodor, Nicholas S. ® Priority: 22.10.85 US 790159 7211 Southwest 97th Lane Gainesville Florida 32608(US) © Date of publication of application: Inventor: Estes, Kerry S. 06.05.87 Bulletin 87/19 5604 Southwest 83rd Drive Gainesville Florida 32608(US) © Designated Contracting States: Inventor: Simpkins, James W. AT BE CH DE ES FR GB GR IT LI LU NL SE 1722 Northwest 11th Road Gainesville Florida 32605(US) © Representative: Pendlebury, Anthony et al Page, White & Fairer 5 Plough Place New Fetter Lane London EC4A 1HY(GB) © Use of estrogen-dihydropyridlne compounds for weight control. © The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridines*pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an I estradiol derivative, namely, 1 7/3-[(1 -methyl-1 ,4-dihydro-3-pyridinyl)carbonyloxy]estra-1 ,3,5(1 0)-trien-3-ol.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,071,531 Jona Et Al
    USOO6071531A United States Patent (19) 11 Patent Number: 6,071,531 Jona et al. (45) Date of Patent: Jun. 6, 2000 54) TRANSDERMAL PATCH AND METHOD FOR 5,376,377 12/1994 Gale et al.. ADMINISTERING 17-DEACETYL 5,393,529 2/1995 Hoffmann et al... NORGESTIMATE ALONE OR IN 5,422,119 6/1995 Casper. COMBINATION WITH AN ESTROGEN 5,474,783 12/1995 Miranda et al.. 5,508,038 4/1996 Wang et al.. 5,560,922 10/1996 Chien et al.. Inventors: Janan Jona, Sunnyvale; Jay Audett, 5,656.286 8/1997 Miranda et al.. Mountain View; Noel Singh, San 5,665,377 9/1997 Gonella et al.. Francisco, all of Calif. 5,711,962 1/1998 Cordes et al.. 5,741,511 4/1998 Lee et al.. Assignee: Ortho-McNeil Pharmaceutical, Inc., 5,762.956 6/1998 Chien et al.. Raritan, N.J. 5,788,983 8/1998 Chien et al.. Appl. No.: 09/340,859 FOREIGN PATENT DOCUMENTS 0 196 769 10/1986 European Pat. Off.. Filed: Jun. 28, 1999 O 295 411 A1 12/1988 European Pat. Off.. O 454 089 A1 10/1991 European Pat. Off.. Related U.S. Application Data 0 235 259 7/1992 European Pat. Off.. 0 705 097 B1 3/1997 European Pat. Off.. Continuation of application No. 09/165,526, Oct. 2, 1998, 0 655 916 B1 2/1998 European Pat. Off.. which is a continuation of application No. 08/660,024, Jun. WO 96/40087 12/1996 WIPO. 6, 1996, Pat. No. 5,876,746, which is a continuation-in-part of application No.
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]